Greater pathogen burden but not elevated c-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention

American Heart Journal

Volumn 144, Issue 3, 2002, Pages 491-500

  Horne, Benjamin D ^a   Muhlestein, Joseph B ^a,b   Strobel, Gunnar G ^b   Carlquist, John F ^a,b   Bair, Tami L ^a   Anderson, Jeffrey L ^b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTERY DIAMETER; ARTICLE; BLOOD SAMPLING; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY OBSTRUCTION; CYTOMEGALOVIRUS; FEMALE; HELICOBACTER PYLORI; HUMAN; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0036733439     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.125010     Document Type: Article

References (41)

1. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
2. Percutaneous transluminal coronary angioplasty in New York State. Risk factors and outcomes
3. Predictive factors of restenosis after coronary stent placement
4. Effect of prior coronary restenosis on the risk of subsequent restenosis after stent placement or directional atherectomy
5. High-speed rotational coronary atherectomy for patients with diffuse coronary artery disease
6. Stenting after optimal lesion debulking (SOLD) registry: Angiographic and clinical outcome
7. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease
8. Influence of diabetes mellitus on early and late outcome after percutaneous coronary angioplasty
9. Inflammation, atherosclerosis, and ischemic events: Exploring the hidden side of the moon
10. Cell biology of atherosclerosis
11. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: Potential role of matrix-degrading metalloproteinases and implications for plaque rupture
12. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
13. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction
14. Production of C-reactive protein and risk of coronary events in stable and unstable angina
15. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
16. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors
17. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction
18. Possible role of cytomegalovirus in atherogenesis
19. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically-demonstrated coronary artery disease
20. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels
21. Prospective study of pathogen burden and risk of myocardial infarction and death
22. Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial
23. A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapies
24. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty: A quantitative angiographic analysis of 3336 lesions
25. Serum cholesterol in patients undergoing cardiac catheterization for suspected coronary artery disease: Diagnostic and prognostic implications
26. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty: The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty
27. Lack of effect on restenosis after coronary angioplasty
28. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial)
29. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae
30. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
31. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease
32. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms
33. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations?
34. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease
35. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis
36. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy
37. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis
38. Prior cytomegalovirus infection and the risk of restenosis after percutaneous transluminal coronary balloon angioplasty
39. Previous cytomegalovirus or Chlamydia pneumoniae infection and risk of restenosis after percutaneous transluminal coronary angioplasty
40. Effect of antibiotic treatment against Chlamydia pneumoniae with roxithromycin on neointima proliferation after coronary stent placement
41. Usefulness of the substitution of nonangiographic end points (death, acute myocardial infarction, coronary bypass and/or repeat angioplasty) for follow-up coronary angiography in evaluating the success of coronary angioplasty in patients with angina pectoris